Beech Biotech SA

Beech Biotech is unlocking novel biology to create breakthrough treatments for preeclampsia and other complications of pregnancy. Each year, preeclampsia causes the deaths of 70,000 mothers, 500,000 babies worldwide. Beyond that, long-term health consequences affect 300 million surviving mothers and their preterm infants. A key unmet need are medicines that treat only the mother without exposing the fetus to additional risk. We are addressing this need by developing “Mother only” monoclonals, achieved by a patented modification that blocks antibodies from crossing the placenta. Our lead asset, MOm303, binds and eliminates maternal sFlt-1, a known cause of vascular breakdown in preeclampsia, and releases placental growth factor, thus restoring the healthy balance of these factors. This has the potential to prolong pregnancy and reduce the consequences of preterm birth